Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on July 31, 2025
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
GlobeNewswire
·
July 31, 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial …
MariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT Holdings
GlobeNewswire
·
July 31, 2025
NORWOOD, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced a strategic agreement with TILT Holdings (“TILT”) (CBOE: …
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
GlobeNewswire
·
July 31, 2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and …
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
July 31, 2025
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90% of ex-U.S. …
Glasswing Ventures Expands Exclusive Advisory Network to Accelerate AI-Native Portfolio Success
GlobeNewswire
·
July 31, 2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Glasswing Ventures, a first capital-in investor in startups applying AI and frontier technology to the enterprise and cybersecurity markets, today announced the appointment of 12 distinguished business and security …
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
GlobeNewswire
·
July 31, 2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
AMG Reports Financial and Operating Results for the Second Quarter and First Half of 2025
GlobeNewswire
·
July 31, 2025
Positive net client cash flows of more than $8 billion, driven by ongoing momentum in private markets and liquid alternatives New partnership with Montefiore Investment further diversifies AMG’s business and expands its participation in private markets …
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
July 31, 2025
$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September …
Prime Medicine Announces Pricing of Public Offering
GlobeNewswire
·
July 31, 2025
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten …